top of page
  • mmahomed2

Phase I SBIR grant from the National Cancer Institute

Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provide sustained immune cell activation after intratumoral injection. Specifically, we will generate a therapeutic product that can be used to generate a system-wide immune response against metastatic melanomas cells after administration to only a subset of surface-accessible lesions.

61 views0 comments

Recent Posts

See All

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised

Valitor has recruited and hired Amy Twite, PhD to join our team as Director Chemistry. Amy graduated from UC Berkeley’s College of Chemistry with extensive experience in conjugation chemistry and cell

bottom of page